{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":11,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":11,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"238d4fe56bae","filters":{"venue":"Expert Opinion on Orphan Drugs"}},"results":[{"id":"W1525227301","doi":"10.1517/21678707.2015.1046434","title":"Pathogenic mechanisms and the prospect of gene therapy for choroideremia","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Retinal Development and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Spark Therapeutics; National Institutes of Health; Canadian Institutes of Health Research; National Institute for Health and Care Research; Alberta Innovates - Health Solutions; National Eye Institute; Wellcome Trust","keywords":"Choroideremia; Medicine; Genetic enhancement; Bioinformatics; Gene; Genetics; Biology; Ophthalmology","authors":[{"name":"Ioannis Dimopoulos","is_ca":true},{"name":"Stephanie Chan","is_ca":true},{"name":"Robert E. MacLaren","is_ca":false},{"name":"Ian M. MacDonald","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01760066621009843,"gpt":0.275906289690686,"spread":0.2583056234805876,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001150988,0.0003748551,0.0005780316,0.0005524429,0.0002927749,0.001126675,0.0005272568,0.0021287,0.003216061],"category_scores_gemma":[0.001117368,0.000125009,0.0004638537,0.0002818147,0.001445185,0.001591287,0.0005091784,0.00309801,0.001501796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007992184,"about_ca_system_score_gemma":0.0007221461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000379792,"about_ca_topic_score_gemma":0.0005610684,"domain_scores_codex":[0.9996794,0.0001047684,0.00002516123,0.00004521576,0.0001110901,0.0000344305],"domain_scores_gemma":[0.9995114,0.0002691671,0.00007172126,0.00002083632,0.00009234459,0.00003454501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.0006272173,0.0001668039,0.001483596,0.006020088,0.0001273136,0.006452132,0.0003546685,0.001374399,0.06527279,0.1747684,0.1224868,0.6208659],"study_design_scores_gemma":[0.00007199363,0.000307969,0.0008008414,0.001879246,0.00009321884,0.008866188,0.000190284,0.0005147648,0.01026627,0.0443982,0.9325728,0.00003822025],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0035529,0.9213173,0.005925498,0.05457897,0.004657623,0.0000255131,0.00007928235,0.00006669053,0.009796196],"genre_scores_gemma":[0.0275307,0.9391885,0.005126335,0.01697404,0.005427954,0.00004435235,0.0001032757,0.00002777252,0.005577111],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003216061,"threshold_uncertainty_score":0.01075876,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560073692","doi":"10.1080/21678707.2017.1264300","title":"Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials","year":2016,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Biobank; Clinical trial; Intensive care medicine; Expert opinion; Incidence (geometry); Cancer; Pathology; Internal medicine; Bioinformatics","authors":[{"name":"Victoria Mandilaras","is_ca":true},{"name":"Katherine Karakasis","is_ca":true},{"name":"Blaise Clarke","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Stéphanie Lheureux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1567302190808919,"gpt":0.4498017616627763,"spread":0.2930715425818844,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0487699,0.0003606923,0.002278975,0.001974535,0.0005311896,0.003697577,0.001850442,0.002181527,0.008587032],"category_scores_gemma":[0.1064782,0.0003273233,0.001564932,0.002948898,0.002343029,0.005058896,0.001910997,0.003486601,0.001419258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0025355,"about_ca_system_score_gemma":0.007982212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001246852,"about_ca_topic_score_gemma":0.001986209,"domain_scores_codex":[0.9753675,0.01599005,0.003593001,0.00140948,0.003161168,0.0004789651],"domain_scores_gemma":[0.7931492,0.1725877,0.01547953,0.004480707,0.01114811,0.003154652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001503753,0.00009413614,0.003951358,0.05059826,0.001033621,0.0003724994,0.0002757811,0.0007369488,0.0005101186,0.02486296,0.06906416,0.8469964],"study_design_scores_gemma":[0.0008211344,0.0008661014,0.005694399,0.1104849,0.002054418,0.001966541,0.0006073533,0.0007336178,0.0007416998,0.03890838,0.8370438,0.00007762353],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.001495297,0.9194115,0.001949406,0.06790537,0.003276479,0.0001402612,0.0005831315,0.00003891028,0.005199544],"genre_scores_gemma":[0.04648751,0.887025,0.009053484,0.0428228,0.01172855,0.0006804932,0.001214563,0.00007864032,0.0009089924],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0487699,"threshold_uncertainty_score":0.257923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4385458457","doi":"10.1080/21678707.2023.2241347","title":"Real world data for rare diseases research: The beginner’s guide to registries","year":2023,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Disease; Medical record; Rare disease; Summary of Product Characteristics; Disease registry; MEDLINE; Product (mathematics); Family medicine; Medical emergency; Data science; Drug; Pathology; Computer science; Pharmacology","authors":[{"name":"Federica Pisa","is_ca":false},{"name":"Ariel E. Arias","is_ca":true},{"name":"Emily W. Bratton","is_ca":false},{"name":"Maribel Salas","is_ca":false},{"name":"Janet Sultana","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1106638838175293,"gpt":0.423275749054378,"spread":0.3126118652368487,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1234814,0.002110498,0.004049533,0.01299841,0.00195739,0.01414288,0.008093286,0.01146379,0.04823659],"category_scores_gemma":[0.328921,0.003518413,0.004253478,0.01479329,0.005279098,0.02234815,0.01150632,0.02034014,0.05339195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003735014,"about_ca_system_score_gemma":0.0233976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007512,"about_ca_topic_score_gemma":0.008386284,"domain_scores_codex":[0.8996174,0.05692278,0.01984767,0.003668883,0.01867673,0.001266462],"domain_scores_gemma":[0.55041,0.2927749,0.01748463,0.05295604,0.07450948,0.01186485],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008533868,0.00006000829,0.0008568098,0.00213167,0.00008392025,0.0002199786,0.0005919019,0.00034847,0.0002005791,0.03335581,0.7436569,0.2184086],"study_design_scores_gemma":[0.00006026706,0.00002648174,0.000521571,0.004596334,0.00002720393,0.00035257,0.0002186669,0.0002668021,0.00009540897,0.02052688,0.9732547,0.00005317105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0007244351,0.06836428,0.2609479,0.5049455,0.02057241,0.005894248,0.04769811,0.0141556,0.0766976],"genre_scores_gemma":[0.007085771,0.1008063,0.684661,0.1078508,0.01869169,0.01278254,0.03607289,0.005179534,0.02686952],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.8765185,"threshold_uncertainty_score":0.6530401,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2737330112","doi":"10.1080/21678707.2017.1359086","title":"Morbidity and mortality associated with Farber disease and prospects for therapy","year":2017,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Montreal Children's Hospital","funders":"National Institutes of Health","keywords":"Medicine; Disease; Intensive care medicine; Adult-onset Still's disease; Internal medicine","authors":[{"name":"Edward H. Schuchman","is_ca":false},{"name":"John J. Mitchell","is_ca":true},{"name":"Alex Solyom","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06523544874345108,"gpt":0.3782282851747972,"spread":0.3129928364313461,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007212434,0.0002867947,0.0007951683,0.0004210883,0.0002913223,0.000839178,0.0004051298,0.0008078553,0.007934645],"category_scores_gemma":[0.00147058,0.0000641147,0.0006914657,0.0004534424,0.0002724641,0.0004721574,0.000397156,0.0009777998,0.001384901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007709453,"about_ca_system_score_gemma":0.0009887716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008210897,"about_ca_topic_score_gemma":0.0009045781,"domain_scores_codex":[0.9997244,0.00008082328,0.00002141469,0.00003857641,0.00007081417,0.00006391978],"domain_scores_gemma":[0.9994456,0.000137654,0.0001292817,0.00001560454,0.0001043457,0.0001674411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001796846,0.0002154232,0.04767153,0.004363365,0.0007644442,0.001651174,0.0001494972,0.001183634,0.001440713,0.01229759,0.1328205,0.7956453],"study_design_scores_gemma":[0.0007730589,0.003446897,0.316192,0.03740708,0.002515891,0.02239737,0.001899967,0.00420285,0.001843165,0.0553876,0.5536737,0.0002603838],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02331422,0.9018477,0.001630056,0.04695125,0.00290904,0.00003879926,0.00175713,0.0001127622,0.02143909],"genre_scores_gemma":[0.239236,0.7340369,0.00194953,0.007014061,0.008722549,0.0001039492,0.003236974,0.00003508357,0.005664834],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007934645,"threshold_uncertainty_score":0.02654409,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3019361312","doi":"10.1080/21678707.2020.1760837","title":"Advances in therapeutic treatment options for ANCA-associated vasculitis","year":2020,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Vasculitis and related conditions","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Rituximab; Maintenance therapy; Intensive care medicine; Guideline; ANCA-Associated Vasculitis; Vasculitis; Cyclophosphamide; Expert opinion; Immunology; Internal medicine; Disease; Chemotherapy; Pathology; Lymphoma","authors":[{"name":"Shealynn Carpenter","is_ca":true},{"name":"Jan Willem Cohen Tervaert","is_ca":true},{"name":"Elaine Yacyshyn","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03436985990012032,"gpt":0.3269259203116747,"spread":0.2925560604115544,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00146561,0.000502005,0.0008465181,0.001143767,0.0002818553,0.001185613,0.0007240726,0.001400426,0.01110158],"category_scores_gemma":[0.002212493,0.0001704814,0.001044197,0.0006011391,0.0004382636,0.00151487,0.0006828607,0.003031167,0.003514032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007440825,"about_ca_system_score_gemma":0.00105177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00113047,"about_ca_topic_score_gemma":0.002547383,"domain_scores_codex":[0.999188,0.0002334473,0.0001003101,0.00009231437,0.000313212,0.00007267534],"domain_scores_gemma":[0.9987622,0.0005574776,0.0001927418,0.00003171244,0.0003749339,0.00008092619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001145237,0.00007758244,0.000427917,0.009027309,0.0001394119,0.0005310435,0.00009387654,0.0004348863,0.001950783,0.008063782,0.1131719,0.865967],"study_design_scores_gemma":[0.00005766498,0.0001009415,0.0006460004,0.006439346,0.0001734182,0.002332838,0.00006907441,0.0002119359,0.0005706371,0.005002055,0.9843763,0.00001971059],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006015155,0.9697754,0.001773662,0.01570209,0.001581014,0.00002403241,0.0001142541,0.00005440984,0.0103735],"genre_scores_gemma":[0.007669339,0.975804,0.003067468,0.007469859,0.002975377,0.00004050691,0.000268911,0.00002114375,0.00268344],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01110158,"threshold_uncertainty_score":0.03713846,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391470543","doi":"10.1080/21678707.2024.2313766","title":"Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing","year":2024,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Arthur B. McDonald-Canadian Astroparticle Physics Research Institute; Fraser Institute; Wilfrid Laurier University; Canadian Institute for Health Information","funders":"","keywords":"Formulary; Medicine; Orphan drug; Listing (finance); Government (linguistics); Negotiation; List price; Pharmacology; Bioinformatics; Business; Finance; Law; Political science","authors":[{"name":"Nigel S. B. Rawson","is_ca":true},{"name":"J. F. Adams","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1247249976088999,"gpt":0.4065759861865942,"spread":0.2818509885776944,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01380133,0.0003044194,0.0006065437,0.004193189,0.001823459,0.003469812,0.001013151,0.0007803392,0.003917939],"category_scores_gemma":[0.05611838,0.0002292235,0.001267832,0.01096139,0.001227436,0.001216745,0.001382188,0.001815798,0.0001407406],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.07211533,"about_ca_system_score_gemma":0.1039272,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9670264,"about_ca_topic_score_gemma":0.9691096,"domain_scores_codex":[0.9890333,0.002122537,0.0008553461,0.0006055426,0.005708216,0.001674974],"domain_scores_gemma":[0.9426674,0.02017329,0.02026661,0.0009064215,0.01242442,0.003561974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005798845,0.0001582925,0.7971786,0.001867034,0.001030242,0.0004307726,0.0008838232,0.008360201,0.0001295259,0.01598248,0.03222426,0.1411749],"study_design_scores_gemma":[0.0001379558,0.0001271605,0.9409635,0.002113556,0.0006691365,0.0002868776,0.001465874,0.0149971,0.000370877,0.004426469,0.0343372,0.0001043803],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.68098,0.1130074,0.007824834,0.1010428,0.0004689817,0.0009971916,0.02730368,0.0001460249,0.06822911],"genre_scores_gemma":[0.9728053,0.01404681,0.003099416,0.003244937,0.0001273915,0.00009069088,0.004982976,0.00002037724,0.001582159],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.9278847,"threshold_uncertainty_score":0.5232358,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2970900708","doi":"10.1080/21678707.2019.1651641","title":"Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome","year":2019,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Defibrotide; Medicine; Hepatic veno-occlusive disease; Transplantation; Disease; Chemotherapy; Intensive care medicine; Clinical trial; Hematopoietic stem cell transplantation; Surgery; Internal medicine","authors":[{"name":"Christine Duncan","is_ca":false},{"name":"Justine M. Kahn","is_ca":false},{"name":"Stephan A. Grupp","is_ca":false},{"name":"Paul G. Richardson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01847546117997082,"gpt":0.2831116279990802,"spread":0.2646361668191094,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007505117,0.0003254954,0.0006924965,0.0009091425,0.000197264,0.0007238853,0.0004697756,0.000822134,0.005994846],"category_scores_gemma":[0.001239459,0.0001088384,0.0006926721,0.0006676046,0.0002718312,0.0008471241,0.0003277121,0.001629303,0.001351407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003647548,"about_ca_system_score_gemma":0.0004835268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004024789,"about_ca_topic_score_gemma":0.001195097,"domain_scores_codex":[0.9997231,0.00007595807,0.00005717508,0.000048055,0.00007063978,0.00002490751],"domain_scores_gemma":[0.9992951,0.000342482,0.0001449431,0.00001574384,0.0001518384,0.00004981162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004469435,0.00009895871,0.0004817101,0.0127308,0.0001882409,0.0006595316,0.00008813792,0.0002910181,0.002765863,0.00338975,0.03707495,0.9417841],"study_design_scores_gemma":[0.0002846078,0.0006818173,0.002218643,0.007185784,0.0005073436,0.003634176,0.0001061623,0.0003484664,0.001519044,0.003258217,0.9802186,0.00003711148],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001261082,0.9875694,0.0004498473,0.004060667,0.001117759,0.00002155494,0.00009457826,0.00001585325,0.005409194],"genre_scores_gemma":[0.01340836,0.9751217,0.001498414,0.004669092,0.002478817,0.00005278205,0.0002659642,0.000008742503,0.002496121],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005994846,"threshold_uncertainty_score":0.02005482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2626803060","doi":"10.1080/21678707.2017.1341307","title":"Ultra-orphan drugs: can we afford the price","year":2017,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Orphan drug; Medicine; Pharmacology; Bioinformatics","authors":[{"name":"Devidas Menon","is_ca":true},{"name":"Tania Stafinski","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2420690762339051,"gpt":0.4302075575686553,"spread":0.1881384813347502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006344472,0.0006620993,0.00112775,0.0009623208,0.001818999,0.006455992,0.001642559,0.01207379,0.05193748],"category_scores_gemma":[0.05181113,0.000285083,0.001036723,0.0008834726,0.004165843,0.01363911,0.002858253,0.01371311,0.01090732],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003312701,"about_ca_system_score_gemma":0.007827349,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01442972,"about_ca_topic_score_gemma":0.02412028,"domain_scores_codex":[0.9959495,0.001247789,0.0002175094,0.0003730696,0.001651029,0.0005611131],"domain_scores_gemma":[0.9869822,0.006249464,0.0009537177,0.0005939768,0.002758879,0.00246184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001557573,0.00003678347,0.0004699407,0.0003145605,0.00004253448,0.0001343864,0.0001424234,0.00009361377,0.0001349263,0.03768678,0.8824816,0.07830674],"study_design_scores_gemma":[0.0000918223,0.00005743753,0.0008881197,0.001606316,0.00004637118,0.0002059182,0.0005551717,0.0001454657,0.0001298263,0.05218139,0.9440526,0.00003943098],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0004273307,0.02796878,0.0003610177,0.9494537,0.008960478,0.00001040135,0.0002501462,0.00003541588,0.0125328],"genre_scores_gemma":[0.0396584,0.09290088,0.001990274,0.7954387,0.04275537,0.0001038153,0.0006168009,0.0002413905,0.02629437],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05193748,"threshold_uncertainty_score":0.1737482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2507172233","doi":"10.1080/21678707.2016.1232649","title":"Applying integrated care systems to rare diseases","year":2016,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Intensive care medicine","authors":[{"name":"Réjean Hébert","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1824855625707687,"gpt":0.4090593145999395,"spread":0.2265737520291708,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01266263,0.0005853131,0.0006169245,0.002607681,0.0008115441,0.004385888,0.001476573,0.00220515,0.009313166],"category_scores_gemma":[0.03414045,0.0002718281,0.001260207,0.003640837,0.001554962,0.003250261,0.005511775,0.002139733,0.0006082579],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007927914,"about_ca_system_score_gemma":0.009578167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02035012,"about_ca_topic_score_gemma":0.01542278,"domain_scores_codex":[0.9893525,0.007411341,0.0005041707,0.0005908428,0.001488711,0.0006523918],"domain_scores_gemma":[0.9882407,0.006365124,0.001137696,0.001004369,0.002547872,0.0007043249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","study_design_scores_codex":[0.000165198,0.0002481113,0.01344753,0.001640173,0.0009220015,0.0004308567,0.0008873963,0.03061173,0.0002743612,0.5059718,0.04751687,0.397884],"study_design_scores_gemma":[0.0004880919,0.0005668664,0.01547175,0.003739125,0.000510809,0.0003936482,0.001601436,0.05294639,0.0007423586,0.6633744,0.2600479,0.0001171633],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.05846935,0.06925553,0.3258689,0.3622032,0.008985045,0.001673983,0.003158365,0.001078444,0.1693071],"genre_scores_gemma":[0.7538657,0.04581563,0.164892,0.02002377,0.005652997,0.001238059,0.001300296,0.0001065486,0.007104999],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02035012,"threshold_uncertainty_score":0.06696719,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2895884786","doi":"10.1080/21678707.2018.1536542","title":"Advances in emerging therapeutics for oculopharyngeal muscular dystrophy","year":2018,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Oculopharyngeal muscular dystrophy; Muscular dystrophy; Internal medicine","authors":[{"name":"Pradeep Harish","is_ca":false},{"name":"George Dickson","is_ca":false},{"name":"Alberto Malerba","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03677599223228073,"gpt":0.3498005528771954,"spread":0.3130245606449146,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001037552,0.0005975995,0.0009504216,0.0008758398,0.0002788584,0.001366768,0.0007118128,0.001491463,0.008608228],"category_scores_gemma":[0.0006636581,0.0001539221,0.0007507928,0.0004999166,0.0004639717,0.001487598,0.0007423558,0.002030093,0.0033106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006286168,"about_ca_system_score_gemma":0.0008892793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000550777,"about_ca_topic_score_gemma":0.001535309,"domain_scores_codex":[0.9996748,0.0000737239,0.00003012091,0.00005829193,0.0001070361,0.00005600435],"domain_scores_gemma":[0.9995758,0.00014083,0.00006453018,0.00001548473,0.0001590017,0.00004439297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004605446,0.0002680808,0.0005382746,0.0101318,0.0001543401,0.000948558,0.0001739448,0.0007878281,0.02707447,0.01600113,0.04745137,0.8960096],"study_design_scores_gemma":[0.0001717023,0.0007731092,0.001013447,0.002686844,0.0002025711,0.001692105,0.0001698926,0.0006072242,0.006621219,0.009462662,0.9765611,0.00003818779],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003106124,0.9736571,0.00295858,0.008966401,0.001794484,0.00004684997,0.0001696474,0.00007503023,0.00922576],"genre_scores_gemma":[0.01730642,0.9671354,0.004307232,0.003896862,0.001639051,0.00008091374,0.0003064008,0.00002184766,0.005305833],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008608228,"threshold_uncertainty_score":0.02879739,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144559222","doi":"10.1517/21678707.2015.1092868","title":"Potential of antisense therapy for facioscapulohumeral muscular dystrophy","year":2015,"lang":"en","type":"article","venue":"Expert Opinion on Orphan Drugs","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Facioscapulohumeral muscular dystrophy; Gene knockdown; Muscular dystrophy; Homeobox; Medicine; Gene; Genetic enhancement; Transcription factor; Genetics; Bioinformatics; Cancer research; Biology","authors":[{"name":"Bo Bao","is_ca":true},{"name":"Toshifumi Yokota","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0193670907872162,"gpt":0.2968967167902125,"spread":0.2775296260029962,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002733443,0.0003589193,0.0004271975,0.0003078211,0.0001253563,0.0004336479,0.0002370453,0.0008458098,0.003776929],"category_scores_gemma":[0.0001830895,0.00006965144,0.0003906876,0.0001366067,0.0002123837,0.0003904616,0.0002300643,0.0007536985,0.001087544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002965615,"about_ca_system_score_gemma":0.0002305195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002982651,"about_ca_topic_score_gemma":0.0007486409,"domain_scores_codex":[0.999882,0.0000287381,0.000009012721,0.00002422018,0.000039904,0.00001599728],"domain_scores_gemma":[0.999938,0.00002548411,0.00001241772,0.000001627438,0.00001648728,0.000006060116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005361515,0.0001995972,0.0006133579,0.00657765,0.0001302668,0.001721138,0.0001816437,0.0008927842,0.2606012,0.015497,0.02192758,0.6911217],"study_design_scores_gemma":[0.0002445491,0.002017563,0.001696664,0.001522412,0.0002724006,0.005725158,0.000176313,0.001277056,0.08839895,0.006480997,0.8921378,0.00005019351],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01880463,0.9391281,0.01483483,0.006388753,0.002633999,0.0001064938,0.0001963108,0.0001153566,0.01779146],"genre_scores_gemma":[0.1215971,0.8436012,0.008660668,0.004608216,0.002109498,0.0001792418,0.0003731271,0.00003900018,0.01883202],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003776929,"threshold_uncertainty_score":0.01263511,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}